Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Humana Inc. (NYSE:HUM)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Humana Inc. (NYSE:HUM). In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Humana stock on April 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of Kinder Morgan NYSE: KMI on 4/29/2025.

Humana Stock Performance

Shares of HUM opened at $253.14 on Thursday. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a market cap of $30.55 billion, a PE ratio of 25.44, a P/E/G ratio of 2.05 and a beta of 0.49. The stock has a 50-day moving average of $265.66 and a 200-day moving average of $270.44. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. During the same quarter in the previous year, the company posted $7.23 earnings per share. The company's quarterly revenue was up 8.4% on a year-over-year basis. On average, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana's dividend payout ratio is currently 25.04%.

Institutional Investors Weigh In On Humana

Several large investors have recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the fourth quarter worth about $27,000. Centricity Wealth Management LLC purchased a new position in Humana in the 4th quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA raised its holdings in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management purchased a new stake in shares of Humana during the fourth quarter worth $33,000. Finally, Riverview Trust Co bought a new position in shares of Humana in the first quarter worth $34,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Guggenheim began coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Finally, Oppenheimer increased their price target on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research report on Thursday, May 1st. Eighteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $287.76.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.